Collaboration for Novel Therapies for Retinal Diseases

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal DiseasesBoehringer Ingelheim strengthens its retinal disease pipeline portfolio with   new co-development and license agreementThe partners aim to develop novel therapies with significantly reduced patient burden for eye diseases with limited or only insufficient treatment options using Inflammasome Therapeutics ’ intravitreal drug delivery technology Inflammasome Therapeutics is entitled to receive up to $160 million in milestone and gated development payments as well as tiered royalties and other milestones due on commercialization 

Source: Boehringer Ingelheim Corporate News - September 20, 2019 Category: Research Source Type: news